The Case Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1826-01-01

Employees: 5K

Market Cap: -

Website: http://www.case.edu/cancer

Clinical Trials

Differentiation Therapy With Decitabine in Treating Patients With Myelodysplastic Syndrome

Phase 1

Completed

Conditions: Chronic Myelomonocytic Leukemia
de Novo Myelodysplastic Syndromes
Myelodysplastic Syndromes
Refractory Anemia
Refractory Anemia With Excess Blasts
Refractory Anemia With Ringed Sideroblasts
Refractory Cytopenia With Multilineage Dysplasia
Thrombocytopenia

Interventions: Other: flow cytometry
Other: DNA methylation analysis
Other: cytogenetic analysis
Drug: decitabine
Genetic: microarray analysis
Genetic: gene expression analysis
Other: pharmacological study
Genetic: polymorphism analysis

First Posted Date: 2010-07-20

Last Posted Date: 2019-03-04

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT01165996

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Sunitinib Malate in Treating Patients With Previously Untreated Metastatic Kidney Cancer

Phase 2

Completed

Conditions: Clear Cell Renal Cell Carcinoma
Stage IV Renal Cell Cancer

Interventions: Drug: sunitinib malate

First Posted Date: 2010-07-08

Last Posted Date: 2018-09-14

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 37

Registration Number: NCT01158222

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Celecoxib and Recombinant Interferon Alfa-2b in Metastatic Kidney Cancer Who Have Undergone Surgery

Phase 2

Completed

Conditions: Renal Cell Cancer
Stage IV Renal Cell Cancer

Interventions: Drug: celecoxib
Biological: recombinant interferon alfa-2b
Other: polymerase chain reaction
Other: laboratory biomarker analysis
Other: reverse transcriptase-polymerase chain reaction
Other: immunologic technique
Other: immunohistochemistry staining method
Other: flow cytometry

First Posted Date: 2010-07-08

Last Posted Date: 2012-08-07

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 17

Registration Number: NCT01158534

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer

Phase 2

Completed

Conditions: Stage II Renal Cell Cancer
Clear Cell Renal Cell Carcinoma
Stage I Renal Cell Cancer
Stage III Renal Cell Cancer

Interventions: Drug: pazopanib hydrochloride
Procedure: therapeutic conventional surgery

First Posted Date: 2010-07-08

Last Posted Date: 2018-09-12

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 25

Registration Number: NCT01158521

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Refractory Multiple Myeloma

Interventions: Drug: azacitidine
Drug: lenalidomide
Drug: dexamethasone
Other: DNA methylation analysis
Other: gene expression analysis
Other: bone marrow aspiration
Other: immunohistochemistry staining method
Other: reverse transcriptase-polymerase chain reaction
Other: flow cytometry

First Posted Date: 2010-07-02

Last Posted Date: 2020-11-16

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 45

Registration Number: NCT01155583

Locations: 🇺🇸
University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: bortezomib
Drug: mitoxantrone hydrochloride
Drug: etoposide
Drug: cytarabine
Other: flow cytometry

First Posted Date: 2010-05-20

Last Posted Date: 2015-08-13

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 3

Registration Number: NCT01127009

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer

Phase 1

Terminated

Conditions: Colon Cancer
Rectal Cancer

Interventions: Drug: lenalidomide
Biological: cetuximab
Other: mutation analysis
Other: polymerase chain reaction
Genetic: polymorphism analysis

First Posted Date: 2010-05-19

Last Posted Date: 2012-03-20

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 3

Registration Number: NCT01126450

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Phase 2

Terminated

Conditions: Transitional Cell Carcinoma of the Bladder
Recurrent Bladder Cancer

Interventions: Drug: sunitinib malate
Other: immunohistochemistry staining method
Other: TdT-mediated dUTP nick end labeling assay
Other: light microscopy
Other: laboratory biomarker analysis

First Posted Date: 2010-05-06

Last Posted Date: 2019-05-01

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 19

Registration Number: NCT01118351

Locations: 🇺🇸
CCF-Fairview Hospital, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance

Phase 2

Completed

Conditions: Iris Melanoma
Recurrent Intraocular Melanoma
Ciliary Body and Choroid Melanoma, Medium/Large Size
Ciliary Body and Choroid Melanoma, Small Size

Interventions: Biological: recombinant interferon alfa-2b
Drug: dacarbazine
Other: laboratory biomarker analysis

First Posted Date: 2010-04-09

Last Posted Date: 2019-02-26

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 38

Registration Number: NCT01100528

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or Stage II Breast Cancer

Phase 2

Withdrawn

Conditions: Ductal Breast Carcinoma in Situ
Estrogen Receptor-negative Breast Cancer
Estrogen Receptor-positive Breast Cancer
HER2-negative Breast Cancer
HER2-positive Breast Cancer
Invasive Ductal Breast Carcinoma
Invasive Lobular Breast Carcinoma
Male Breast Cancer
Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate
Mucinous Ductal Breast Carcinoma

Interventions: Radiation: external beam radiation therapy
Other: questionnaire administration
Procedure: therapeutic conventional surgery

First Posted Date: 2010-04-09

Last Posted Date: 2011-12-08

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT01100489

Locations: 🇺🇸
UH-Chagrin Highlands, Orange Village, Ohio, United States
🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
UH-Westlake, Westlake, Ohio, United States

Home Terms & Conditions Privacy Policy